1
|
Aoyama R, Nishikubo H, Kawabata K, Kanei S, Yamamoto Y, Nishimura S, Yashiro M. Clinical Significance of Multi-Cancer Genome Profiling: Data from a Single Hospital in Japan. Cancer Genomics Proteomics 2024; 21:79-87. [PMID: 38151295 PMCID: PMC10756342 DOI: 10.21873/cgp.20431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 11/25/2023] [Accepted: 11/29/2023] [Indexed: 12/29/2023] Open
Abstract
BACKGROUND/AIM Multi-cancer genome profiling (multi-CGP) testing intends to predict the therapeutic efficacy of anticancer medication treatments for eligible patients as part of "precision cancer care." The number of cases in which a new treatment was applied based on multi-CGP testing has been reported to be between 10% and 20% for all patients in Japan. This study aimed to determine the significance of multi-CGP testing in Japan by analyzing clinical data from multi-CGP testing in various solid cancers at our Hospital. PATIENTS AND METHODS A total of 230 patients examined by one of three tests for multi-CGP including NCC Oncopanel, FoundationOne CDx, and FoundationOne Liquid were retrospectively enrolled. Adequate treatment for each patient was discussed at the expert panel meeting according to the results from the genome profiling tests. RESULTS The most frequent cancer types enrolled in this study were pancreas cancer, bowel cancer, and biliary cancer. Of the 230 cases, 106 (46%) were druggable cases, and 21 (9.1%) were administered medication. Partial response (PR) effect was found in 7 (33.3%) of the 21 cases, of which 3 were biliary cancer and 3 had a BRCA2 mutation. Of all the 21 cases, 7 (33.3%) had the maximum treatment benefit of PR. Three cases of biliary tumors were found in the 7 PR cases within the 21 cases. CONCLUSION Of 230 patients, 21 were administered medication following multi-CGP testing data, especially frequent in biliary tumor patients. Multi-CGP testing might be particularly beneficial to patients with biliary tumors in Japan.
Collapse
Affiliation(s)
- Rika Aoyama
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| | - Hinano Nishikubo
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| | - Kyoka Kawabata
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| | - Saki Kanei
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| | - Yurie Yamamoto
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| | - Sadaaki Nishimura
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
- Department of Gastroenterological Surgery, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
- Cancer Center for Translational Research, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| | - Masakazu Yashiro
- Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan;
- Department of Gastroenterological Surgery, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
- Cancer Center for Translational Research, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
2
|
Torimura A, Kanei S, Shimizu Y, Baba T, Uotani R, Sasaki SI, Nagase D, Inoue Y, Ochiya T, Miyazaki D. Profiling miRNAs in tear extracellular vesicles: a pilot study with implications for diagnosis of ocular diseases. Jpn J Ophthalmol 2024; 68:70-81. [PMID: 37947908 DOI: 10.1007/s10384-023-01028-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Accepted: 09/22/2023] [Indexed: 11/12/2023]
Abstract
PURPOSE To estimate the roles of extracellular vesicles (EVs) in tears and to determine whether their profiles are associated with the type of ocular disease. STUDY DESIGN Cross-sectional study. METHODS Tear EVs were extracted from 14 healthy participants and from 21 patients with retinal diseases (age-related macular degeneration [AMD] or diabetic macular edema [DME]). The surface marker expression of tear EVs was examined, and microRNAs (miRNAs) were extracted and profiled by use of real-time PCR array. The stability of the expression of the miRNAs was determined, and their functions were assessed by network analyses. Classification accuracy was evaluated by use of a random forest classifier and k-fold cross-validation. RESULTS The miRNAs that were highly expressed in tear EVs were miR-323-3p, miR-548a-3p, and miR-516a-5p. The most stably expressed miRNAs independent of diseases were miR-520h and miR-146b-3p. The primary networks of the highly stably expressed endogenous miRNAs were annotated as regulation of organismal injury and abnormalities. The highly expressed miRNAs for severe retinal disease were miR-151-5p for AMD and miR-422a for DME, suggesting potential roles of tear EVs in liquid biopsy. Nine miRNAs (miR-25, miR-30d, miR-125b, miR-132, miR-150, miR-184, miR-342-3p, miR-378, and miR-518b) were identified as distinguishing individuals with AMD from healthy individuals with a classification accuracy of 91.9%. CONCLUSIONS The finding that tear EVs contain characteristic miRNA species indicates that they may help in maintaining homeostasis and serve as a potential tool for disease diagnosis.
Collapse
Affiliation(s)
- Airu Torimura
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Saki Kanei
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Yumiko Shimizu
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Takashi Baba
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Ryu Uotani
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Shin-Ichi Sasaki
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Daisuke Nagase
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Yoshitsugu Inoue
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Takahiro Ochiya
- Department of Molecular and Cellular Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Dai Miyazaki
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan.
| |
Collapse
|